Severe asthma in obese patients: Improvement of lung function after treatment with omalizumab

Oliveira, Maria João; Vieira, Manuela; Coutinho, Daniel; Ladeira, Inês; Pascoal, Ivone; Ferreira, José Alberto; Silva, J.M. da; Carvalho, Aurora; Lima, Ricardo

doi:10.1016/j.pulmoe.2018.01.005

Cited by 23 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After 26 weeks of omalizumab treatment, the inverse correlation between ACT scores and BMI of obese patients remained (Figure 1D). These data indicate that omalizumab can improve asthma control for both obese and non‐obese patients reflected in increasing ACT scores as previously described, 8 but omalizumab might not be enough to provide sufficient levels of clinical benefits for all obese patients. This is further supported by the data of lung function tests in Figure 1E,F, showing that only non‐obese patients showed improvements of FEV1 (% predicted; Figure 1E) and FVC (% predicted; Figure 1F) after omalizumab treatment.…”

Section: Figuresupporting

confidence: 67%

Obesity influences the outcomes of anti‐IgE (omalizumab) therapy of asthma

Upchurch

Mamaril-Davis

et al. 2020

Clin Experimental Allergy

View full text Add to dashboard Cite

Section: Figuresupporting

confidence: 67%

Obesity influences the outcomes of anti‐IgE (omalizumab) therapy of asthma

Upchurch

Mamaril-Davis

et al. 2020

Clin Experimental Allergy

View full text Add to dashboard Cite

“…In a recent case report, Peterson and Coop described successful longterm use of omalizumab for exercise-induced anaphylaxis (EIA) in a subject who was refractory to traditional therapy (Peterson and Coop, 2017). Moreover, Oliveira et al described the positive effects of omalizumab therapy, demonstrating a reduction of rescue medications and asthma exacerbations in the studied population; moreover, they reported an improved lung function in obese patients (Oliveira et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study

et al. 2020

View full text Add to dashboard Cite

Asthma is a chronic inflammatory airway disease, representing one of the most severe pathologies in developed countries. Based on a report of the World Health Organization (WHO), it affects about 300 million people worldwide. Few studies have analyzed the effects of daily life physical activity (PA) levels in patients with asthma: moreover, little research has been carried out on PA levels in patients suffering from severe asthma (SA). This study aimed to investigate the PA levels in two groups of patients suffering from SA; in particular, this study analyzed the changes that occur in patients treated with biologic therapy (BT group) and patients who underwent traditional treatment (TT group) over 6 months. Moreover, this study represents a pilot study because, to the best of our knowledge, it is the first investigation that analyzed if the kind of biologic drug (omalizumab or mepolizumab) can produce differences in the PA levels of SA patients. Fifty SA patients were enrolled and PA parameters were monitored for 6 months. Subjects were divided into two treatment groups: TT (20 patients) and BT (30 patients), the BT group was further subdivided according to the drugs used (15, omalizumab; 15, mepolizumab). During drug treatment, all subjects improved their PA levels: indeed, considering the intragroup variation, the PA levels were significantly higher comparing the T6 levels to baseline (T0, p < 0.01). Considering the intragroup variation, it is very interesting to note that biologic therapy improved PA levels compared to the effects of traditional therapy; while at T0 there were no significant differences in the steps per day (SPD) values between the two groups (T0, p = 0.85), the differences become statistically significant at T1, T3, and T6 (T1, p = 0.019; T3, p = 3.48x10 −6 ; T6, p = 4.78x10 −10). As expected, the same differences were reported analyzing the energy expenditure data. In

show abstract

“…Some studies have demonstrated a reduction in exacerbations with omalizumab [58,59], and limited studies have also shown an improvement in lung function [60,61]. Evidence suggests that omalizumab remains effective after discontinuation (table 1) [62,63], implying disease-modifying potential.…”

Section: Anti-igementioning

confidence: 99%

Holy Grail: the journey towards disease modification in asthma

Busse

Menzies‐Gow

2022

Eur Respir Rev

View full text Add to dashboard Cite

At present, there is no cure for asthma, and treatment typically involves therapies that prevent or reduce asthma symptoms, without modifying the underlying disease. A “disease-modifying” treatment can be classed as able to address the pathogenesis of a disease, preventing progression or leading to a long-term reduction in symptoms. Such therapies have been investigated and approved in other indications, e.g. rheumatoid arthritis and immunoglobulin E-mediated allergic disease. Asthma's heterogeneous nature has made the discovery of similar therapies in asthma more difficult, although novel therapies (e.g. biologics) may have the potential to exhibit disease-modifying properties. To investigate the disease-modifying potential of a treatment, study design considerations can be made, including: appropriate end-point selection, length of trial, age of study population (key differences between adults/children in physiology, pathology and drug metabolism) and comorbidities in the patient population. Potential future focus areas for disease-modifying treatments in asthma include early assessments (e.g. to detect patterns of remodelling) and interventions for patients genetically susceptible to asthma, interventions to prevent virally induced asthma and therapies to promote a healthy microbiome. This review explores the pathophysiology of asthma, the disease-modifying potential of current asthma therapies and the direction future research may take to achieve full disease remission or prevention.

show abstract

Severe asthma in obese patients: Improvement of lung function after treatment with omalizumab

Cited by 23 publications

References 27 publications

Obesity influences the outcomes of anti‐IgE (omalizumab) therapy of asthma

Obesity influences the outcomes of anti‐IgE (omalizumab) therapy of asthma

Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study

Holy Grail: the journey towards disease modification in asthma

Contact Info

Product

Resources

About